ArticleBMC gastroenterology2025
Prognostic comparison between LNM and MaVI of hepatocellular carcinoma: a multicenter population-based propensity scores matching study.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) with lymph node metastases (LNM) is an uncommon neoplasm and has an ambivalent prognosis compared to the common type of HCC with macrovascular invasion (MaVI).
methodsIn this study, the clinical data of patients were extracted from Surveillance, Epidemiology, and End Results (SEER) and Southeast Big Data Institute of Hepatobiliary Health, Mengchao Hepatobiliary Hospital of Fujian Medical University. The K-M survival curve described overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS) between LNM and MaVI. Prognostic factors were identified by univariate and multivariate Cox regression analysis. Additionally, propensity score matching (PSM) was performed to minimize the potential confounding factors to facilitate a more reliable conclusion.
resultsA total of 3,326 HCC patients were included in our study. In the SEER cohort, after PSM, the 1-, 3-, and 5-year OS rates were 41.1%, 13.8%, and 8.8% in Group LNM and 28.3%, 11.0%, and 7.1% in Group MaVI (p < 0.001). The 1-, 3-, and 5-year CSS rates were 46.5%, 17.6%, and 12.0% in Group LNM and 32.2%, 14.3%, and 9.7% in Group MaVI (p < 0.001). Multivariate Cox analysis showed that LNM had better OS (HR = 0.79, 95% CI = 0.71-0.89, p < 0.001) and CSS (HR = 0.78, 95% CI = 0.70-0.88, p < 0.001) compared to MaVI. In the hospital cohort, the 1-, 3-, and 5-year OS rates were 57.5%, 42.6%, and 36.3% in Group LNM and 56.3%, 27.4%, and 14.3% in Group MaVI (p = 0.038). The 1-, 3-, and 5-year RFS rates were 40.7%, 32.3%, and 23.5% in Group LNM and 28.9%, 13.0%, and 5.7% in Group MaVI (p = 0.015). Multivariate Cox analysis revealed similar OS (HR = 0.83, 95% CI = 0.57-1.23, p = 0.361) and CSS (HR = 0.76, 95% CI = 0.53-1.10, p = 0.142) between LNM and MaVI.
conclusionThis study found that the current HCC AJCC TNM staging system cannot accurately distinguish the prognosis of LNM and MaVI patients. For patients undergoing hepatectomy, HCC with LNM may obtain a better prognosis than that of HCC with MaVI. Future research requires additional clinical data to further corroborate this finding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.